EQS-News: BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
Retrieved on:
Venerdì, Luglio 21, 2023
Diamond, Pressure, SIX Swiss Exchange, Hyperglycemia, BB Biotech, Insulin, CMS, Investment, Diarrhea, Net asset value, Frankfurt Stock Exchange, Politics, Biogen, Biotechnology, Policy, Dow Jones, Survival, Clinical trial, Diabetes, NAV, NSCLC, Lung cancer, Rash, Ionis, PI3K, US, Inflation, Agios, SOD1, Patient, FTSE Italia Mid Cap, EGFR, NBI, United States dollar, Sickle cell disease, Merck, Inflation Reduction Act of 2022, Neoplasm, FDA, Therapy, CHF, News, ALS, BB, Pharmaceutical industry, Cryptocurrency, Bank, Vertex, Efgartigimod alfa, USD, EUR, Pembrolizumab
BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
Key Points:
- BB BIOTECH AG: Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
The issuer is solely responsible for the content of this announcement. - Media release as at July 21, 2023
Interim report of BB Biotech AG as at June 30, 2023
Sector rotation and fund outflows weigh on biotech stocks, but positive developments allow fund raising to strengthen industry
The first half of 2023 has been disappointing for biotech investors. - This delisting will lower BB Biotech’s administrative costs and BB Biotech shareholders will still be able to buy and sell BB Biotech shares in EUR on the Frankfurt Stock Exchange.
- The quarterly report of BB Biotech AG as at June 30, 2023, can be downloaded at report.bbbiotech.ch/Q223 or www.bbbiotech.com .